WO2017082479A1 - Pharmaceutical composition for prevention or treatment of obesity comprising bean germinated embryo extract - Google Patents

Abstract

The present invention relates to a pharmaceutical composition for prevention or treatment of obesity comprising a bean germinated embryo extract and, specifically, to a pharmaceutical composition for preventing or treating obesity comprising a bean germinated embryo extract or a fraction thereof, a method for preventing or treating obesity including a step of administering the composition to an individual other than a human, and a food composition and a feed composition for preventing or ameliorating obesity comprising a bean germinated embryo extract or a fraction thereof. The bean germinated embryo extract of the present invention inhibits the differentiation of adipocytes, reduces the size thereof, and converts white adipocytes to brown adipocytes, thereby suppressing the accumulation of unnecessary fat in vivo, and thus, can be usefully used for preventing or treating obesity.

Description

Pharmaceutical composition for the prevention or treatment of obesity comprising soybean germ extract

The present invention relates to a pharmaceutical composition for the prevention or treatment of obesity comprising soybean germination extract, specifically, a composition for the prevention or treatment of obesity comprising soybean germination extract or a fraction thereof, the composition except the human It relates to a method for preventing or treating obesity, comprising the step of administering to, a food composition for preventing or improving obesity, including a soybean germ extract or a fraction thereof, and a feed composition.

Obesity (Obesity) or obesity is a state in which fat is excessively accumulated in the body, which is a general term for a state in which fat is increased due to an increase in the number of adipocytes in adipocytes or an increase in the size of adipocytes. Obesity itself may not be a problem, but the social complications caused and the secondary complications caused by excess fat are severe. For example, obesity causes diseases such as hypertension, hyperlipidemia, heart disease, diabetes, arteriosclerosis, fatty liver, joint abnormalities, arthritis, sexual dysfunction, and cancer. In particular, once made fat cells are reduced in size, and because they are not naturally removed and remain in the body permanently, interest for the prevention and treatment of obesity is increasing.

To prevent or treat obesity, and to maintain a good weight requires a balanced diet and regular exercise. In recent years, obesity can be treated by taking drugs that reduce fat absorption. These diet pills can cause side effects such as cardiovascular disease and stroke, such as high blood pressure, and if you stop taking them, Cases often occur. In the case of severe obesity, surgery is performed to remove fat, to limit the amount of food the body can digest, or to perform surgery such as satellite surgery or gastric band insertion, but there are reports of side effects or complications. And even deaths have been reported.

Accordingly, the development of anti-obesity drugs with low toxicity and side effects are urgently required, and recently, alternative methods or preparation methods of various extracts using active ingredients derived from natural products such as herbal medicines and foods have been studied. For example, the composition for the prevention and treatment of obesity, including the extract of the herbal medicine (Korean Patent Publication No. 2015-0105563) or the composition for the improvement, prevention or treatment of obesity, including garlic and Yeoju extract (Korea Patent Publication 2015- 0085543) has been developed. However, the development of a natural pharmaceutical composition or its raw material, which is superior to existing synthetic pharmaceutical compositions for obesity and has fewer side effects, has yet to be developed.

The present inventors have diligently researched to develop a therapeutic agent for obesity using natural-derived ingredients. As a result, the extract of soybean germination embryos produced by germinating soybean embryos discarded in the manufacturing process of processed products using soybeans suppresses the differentiation of fat cells. By reducing the size of fat cells, and converting white fat cells into brown fat cells to confirm that the inhibition of unnecessary fat accumulation in vivo, the present invention was completed.

One object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of obesity comprising soybean germ extract or fractions thereof.

Another object of the present invention is to provide a method for preventing or treating obesity, comprising administering the composition to a subject other than a human.

Another object of the present invention to provide a food composition for the prevention or improvement of obesity comprising soybean germ extract or fractions thereof.

Another object of the present invention is to provide a feed composition for the prevention or improvement of obesity comprising soybean germ extract or fractions thereof.

The soybean germ extract of the present invention inhibits the differentiation of adipocytes, reduces the size, and inhibits the accumulation of unnecessary fat in vivo by converting white adipocytes into brown adipocytes, and thus can be usefully used for the prevention or treatment of obesity. Can be.

1 is a graph showing the toxicity of soybean germ extract to the fat precursor cell line 3T3-L1. Soybean germ extracts were treated at concentrations of 50, 100, 200, 300, 400 and 500 μg / mL.

2 is a graph showing the effect of soybean germ extract on adipocyte differentiation. After inducing differentiation of adipocytes, soybean germ extracts were prepared at concentrations of 50, 100, 200, 300, 400 and 500 μg / mL and treated with the cells, and 100 μM of CLA (conjugated linoleic acid) as a positive control. ). Control refers to undifferentiated control adipocytes, and control + insulin refers to differentiated control adipocytes. Soybean germination extract was prepared at a concentration of 500 μg / mL and treated to the cells.

Figure 3 shows the effect of soybean germination extract (SA) and soybean germination extract (SG) on gene expression associated with adipocyte differentiation, A is a Western blot image showing the amount of gene expression, B is the expression amount This graph shows the result of quantification. PPARγ, SREBP-1c and CEBPα are genes that promote differentiation of adipocytes, and Actin gene was used as a control for comparing expression levels of the genes.

Figure 4 shows the effect of soybean germ extract on fat cell size, A is an image showing the size of fat cells, B is a graph showing the result of measuring the size. Obesity-induced mice (OVX) were surgically removed and used as a negative control group. Soybean germination ingestion was administered to the mice with 0.1 mg / kg, 1 mg / kg and 5 mg / kg soybean germ extracts. Used as a group.

Figure 5 shows the effect of soybean germ extract on white fat cells and brown fat cells, A is an image showing the size of white fat cells, B is a measure of the number of brown fat cells to the number of white fat cells This graph shows the results. Obesity-induced mice (OVX) were surgically removed and used as a negative control group. Soybean germination ingestion was administered to the mice with 0.1 mg / kg, 1 mg / kg and 5 mg / kg soybean germ extracts. Used as a group.

One aspect for achieving the above object provides a pharmaceutical composition for the prevention or treatment of obesity comprising soybean germ extract or fractions thereof.

As used herein, the term "bean germination embryo" refers to a germinated embryo that germinates an embryo isolated from soybean. The method for producing soybean germ has been known by the inventors' prior studies (Korean Patent Laid-Open No. 2013-0057173), and specifically, the soybean germ may be obtained by germinating embryos separated from soybeans. It is not limited to this. The anti-obesity effect of the soybean germ extract was not known at all, and was first identified by the present inventors.

The soybean germ extract of the present invention may be obtained by extracting the soybean germ with water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.

As used herein, the term "extract" refers to an extract obtained by extracting soybean germ, a diluent or concentrate of the extract, a dried product obtained by drying the extract, a crude or purified product of the extract, or a mixture thereof. It includes the extract itself and extracts of all formulations that can be formed using the extract.

In the soybean germination extract of the present invention, the method of extracting the soybean germination embryo is not particularly limited, and may be extracted according to a method commonly used in the art. Non-limiting examples of the extraction method, hot water extraction method, ultrasonic extraction method, filtration method, reflux extraction method, and the like, these may be performed alone or in combination of two or more methods.

The kind of the extraction solvent used to extract the soybean germ in the present invention is not particularly limited, and any solvent known in the art may be used. Non-limiting examples of the extraction solvent may include water, alcohol or a mixed solvent thereof, these may be used alone or may be used in combination of one or more. When using alcohol as a solvent, specifically, the C1-C4 alcohol can be used.

As used herein, the term "fraction" refers to the result obtained by performing fractionation to separate a specific component or a specific component group from a mixture comprising various various components.

The fractionation method of obtaining the fraction in the present invention is not particularly limited, and may be performed according to a method commonly used in the art. As a non-limiting example of the fractionation method, a method of obtaining a fraction from the extract by treating the extract obtained by extracting the soybean germination of the present invention with a predetermined solvent.

The kind of the fractionation solvent used to obtain the fraction in the present invention is not particularly limited, and any solvent known in the art may be used. Non-limiting examples of the fractionation solvents include polar solvents such as water and alcohols; And nonpolar solvents such as hexane, ethyl acetate, chloroform, dichloromethane, and the like. These may be used alone or in combination of one or more. In the case of using alcohol in the fractionation solvent, an alcohol having 1 to 4 carbon atoms may be used.

Soybean germination extract of the present invention may be to inhibit the differentiation of fat cells.

As used herein, the term "differentiation of adipocytes" means the conversion of adipocytes into adipocytes, and for the purposes of the present invention, means adipocytes accumulate fat in cells.

In one embodiment of the present invention, soybean germination extract was confirmed to reduce fat contained in fat cells to a similar degree as the experimental group treated with CLA (conjugated linoleic acid), which is also used as a dietary supplement It was confirmed that the effect is better than the extract obtained by germinating itself (Fig. 2). This suggests that the extract has an effect of removing excess accumulated fat and thus can be effectively used for treating obesity.

In addition, the soybean germination extract of the present invention may be to reduce the size of fat cells.

As used herein, the term "size of fat cells" means the diameter of fat cells. Since the size of the cell is determined by the amount of fat accumulated in the cell, the decrease in the size of the adipocyte may be a decrease in the amount of fat in the cell.

In one embodiment of the present invention, as a result of administering the extract to an animal model inducing obesity due to menopause, it was confirmed that the diameter including the short axis and the long axis length of the adipocytes was reduced (FIG. 4). This suggests that the extract has an effect of reducing the amount of fat in adipocytes, and thus can be effectively used for the treatment of obesity.

In addition, the soybean germination extract of the present invention may be to convert white fat cells into brown fat cells.

As used herein, the term "white adipocyte" refers to a fat cell that stores fat and is a cell that causes adult diseases such as diabetes and obesity.

As used herein, the term "brown adipocyte" refers to a cell that burns fat into energy and is a cell that plays an important role in thermoregulation and energy production.

When white fat cells are converted to brown fat cells, the amount of fat that is burned increases compared to the fat stored in the body, so it is easier to maintain weight even when the same calorie food is eaten.

In one embodiment of the present invention, as a result of administering the extract to an animal model inducing obesity due to menopause, it was confirmed that the number of brown fat cells increased, and at the same time the size of white fat cells decreased (Fig. 5). This suggests that the extract has an effect of inhibiting the accumulation of fat by converting white fat cells into brown fat cells, and thus can be effectively used for treating obesity.

As used herein, the term "obesity" means a state in which adipose tissue is excessive in the body. Men are said to be obese when their body fat is more than 25% of their body weight, and women are more than 30% of their body weight, and obesity occurs when the amount of calories consumed by food is greater than the calories they consume. Obesity can appear fat and seem easy to breathe, joint pain, diabetes, hypertension and other symptoms can be accompanied.

As used herein, the term "prevention" means any action that inhibits or delays obesity by administration of a pharmaceutical composition comprising the extract of the present invention.

As used herein, the term "treatment" refers to any action by which administration of the pharmaceutical composition improves or advantageously alters the symptoms of a suspected and obese individual.

The pharmaceutical composition of the present invention may include 0.0001 to 50% by weight of the extract relative to the total weight of the composition, and may specifically include 0.01 to 10% by weight, but is not limited thereto.

The pharmaceutical composition of the present invention may further include a pharmaceutically acceptable carrier, excipient or diluent commonly used in the manufacture of the pharmaceutical composition, and the carrier may include a non-naturally occuring carrier. Can be.

The term "pharmaceutically acceptable" in the present invention means to exhibit properties that are not toxic to cells or humans exposed to the composition.

Specifically, the pharmaceutical composition may be formulated in the form of oral dosage forms, external preparations, suppositories, and sterile injectable solutions, such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, respectively, according to conventional methods. Can be. In the present invention, carriers, excipients and diluents that may be included in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, Calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used. Solid form preparations for oral administration include tablets, pills, powders, granules, capsules and the like, and such solid form forms at least one excipient such as starch, calcium carbonate, sucrose or lactose. (lactose), gelatin, etc. are mixed and prepared. In addition to simple excipients, lubricants such as magnesium styrate and talc are also used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.

One aspect for achieving the above object provides a method for preventing or treating obesity comprising administering the composition to a subject other than a human.

The term "administration" of the present invention means introducing a certain substance into an individual in a suitable manner.

The term "individual" of the present invention means all animals, such as rats, mice, livestock, and the like, including humans who may or may develop obesity. As a specific example, it may be a mammal including a human.

Specifically, the method for preventing or treating obesity may include administering a pharmaceutical composition for preventing or treating obesity, including a soybean germination extract or a fraction thereof, to an individual except a human in a pharmaceutically effective amount. have.

As used herein, the term “pharmaceutically effective amount” means an amount sufficient to treat the disease at a reasonable benefit / risk ratio applicable to medical treatment and that does not cause side effects, and the effective dose level is the sex, age of the patient. And other medical fields, including body weight, health status, type of disease, severity, drug activity, drug sensitivity, method of administration, time of administration, route of administration, and rate of release, duration of treatment, combination or drug used It can be easily determined by those skilled in the art according to factors well known in the art.

Specifically, the composition of the present invention may be administered at 0.0001 to 100 mg / kg body weight per day, more specifically at 0.001 to 100 mg / kg body weight, based on solids. Dosing may include administering the recommended dose once daily, or in divided doses.

In the method for preventing or treating obesity of the present invention, the route of administration and the mode of administration of the composition are not particularly limited, and any route of administration and administration can be achieved as long as the composition comprising the composition can reach the desired site. You can follow the way. Specifically, the composition may be administered through various routes, oral or parenteral, and non-limiting examples of the route of administration include oral, rectal, topical, intravenous, intraperitoneal, intramuscular, intraarterial, transdermal, nasal What is administered through intralateral or inhalation etc. are mentioned.

One aspect to achieve the above object provides a food composition for the prevention or improvement of obesity comprising soybean germ extract or fractions thereof.

As used herein, the term " improvement " means any activity in which obesity is improved or advantageously changed by administration of the composition.

The term "food" of the present invention, meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, drinks, tea, drinks, alcoholic beverages , Vitamin complexes, nutraceuticals and health foods, and includes all foods in the usual sense.

The functional food (functional food) is the same term as a food for special health use (Food for special health use, FoSHU), in addition to the nutritional supply, the processed food, so that the bioregulatory function appears efficiently, high medical effect Means food. Here, the term 'function' means to obtain useful effects on health use such as nutrient control or physiological action on the structure and function of the human body. The food of the present invention may be prepared by a method commonly used in the art, and the preparation may be performed by adding raw materials and ingredients commonly added in the art. In addition, the formulation of the food may also be prepared without limitation as long as the formulation is recognized as a food. Food composition of the present invention can be prepared in various forms of formulation, unlike the general medicine has the advantage that there is no side effect that can occur when taking a long-term use of the drug as a raw material, and excellent portability, the present invention Foods can be taken as a supplement to enhance the effect of preventing or improving obesity.

The health food refers to foods having active health maintenance or promotion effect as compared to general foods, and the health supplement food refers to foods for health supplementation purposes. In some cases, the terms nutraceutical, health food, dietary supplement are used.

Specifically, the health functional food is a food prepared by adding the extract of the present invention to food materials such as beverages, teas, spices, gums, confections, or the like, encapsulated, powdered, suspensions, etc. Means to bring effect, but unlike the general medicine has the advantage that there is no side effect that can occur when taking the drug as a raw material for a long time.

Since the food composition of the present invention can be consumed on a daily basis, since a high effect can be expected for the prevention or improvement of obesity, it can be very usefully used.

The food composition may further include a physiologically acceptable carrier, and the type of carrier is not particularly limited and may be any carrier that is commonly used in the art.

In addition, the food composition may include additional ingredients that are commonly used in food compositions to improve the smell, taste, time and the like. For example, it may include vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folate, panthotenic acid, and the like. In addition, minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), copper (Cu) and chromium (Cr) may be included. It may also contain amino acids such as lysine, tryptophan, cysteine, valine and the like.

In addition, the food composition is a preservative (potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetic acid, etc.), fungicides (bleaching powder and highly bleaching powder, sodium hypochlorite, etc.), antioxidants (butylhydroxyanisol (BHA), butylhydride) Oxytoluene (BHT), etc.), colorant (such as tar pigment), colorant (sodium nitrite, sodium nitrite, etc.), bleach (sodium sulfite), seasoning (MSG glutamate, etc.), sweetener (ducin, cyclate, saccharin Foods such as sodium, etc.), fragrances (vanillin, lactones, etc.), swelling agents (alum, potassium D-tartrate, etc.), reinforcing agents, emulsifiers, thickeners (foils), coatings, gum herbicides, foam inhibitors, solvents, modifiers It may include food additives. The additive may be selected according to the type of food and used in an appropriate amount.

The extract of the present invention may be added as it is or used with other food or food ingredients, and may be appropriately used according to conventional methods. The mixed amount of the active ingredient can be suitably determined according to the purpose of use (prevention, health or therapeutic treatment). In general, the food composition of the present invention may be added in an amount of 50 parts by weight or less, specifically 20 parts by weight or less based on the food or beverage in the manufacture of food or beverage. However, when ingested for a long time for the purpose of health and hygiene, it may include the content below the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range.

An example of the food composition of the present invention may be used as a health beverage composition, in which case it may contain various flavors or natural carbohydrates and the like as additional ingredients, such as a general beverage. The above-mentioned natural carbohydrates include monosaccharides such as glucose and fructose; Disaccharides such as maltose and sucrose; Polysaccharides such as dextrin, cyclodextrin; Sugar alcohols such as xylitol, sorbitol, and erythritol. Sweeteners include natural sweeteners such as taumartin, stevia extract; Synthetic sweeteners such as saccharin and aspartame; The ratio of the natural carbohydrate may generally be about 0.01 to 0.04 g, specifically about 0.02 to 0.03 g, per 100 mL of the health beverage composition of the present invention.

In addition to the above, the health beverage composition includes various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid, salts of pectic acid, alginic acid, salts of alginic acid, organic acids, protective colloid thickeners, pH regulators, stabilizers, preservatives, glycerin, Alcohol or carbonation agent and the like. Others may contain fruit flesh for the production of natural fruit juices, fruit juice drinks, or vegetable drinks. These components can be used independently or in combination. Although the ratio of such an additive is not critical, it is generally selected from the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the health beverage composition of the present invention.

Food composition of the present invention may include a variety of weight percent if it can exhibit the effect of preventing or improving obesity, specifically, the extract of the present invention to 0.00001 to 100% by weight or 0.01 to 80% by weight relative to the total weight of the food composition It may include, but is not limited thereto.

One aspect for achieving the above object provides a feed composition for the prevention or improvement of obesity comprising soybean germ extract or fractions thereof.

As used herein, the term "feed" means any natural or artificial diet, meal, or the like or component of such meal for the animal to eat, ingest, and digest.

The feed may comprise feed additives or feed supplements.

The kind of the feed is not particularly limited, and may be used a feed commonly used in the art. Non-limiting examples of the feed may include plant feeds such as cereals, fruits, food processing by-products, algae, fibres, pharmaceutical by-products, oils, starches, gourds or grain by-products; And animal feeds such as proteins, minerals, fats and oils, minerals, fats and oils, single cell proteins, zooplankton or foods. These may be used alone or in combination of two or more thereof.

Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the following examples are only for illustrating the present invention, and the scope of the present invention is not limited thereto.

Example 1 Cytotoxicity Evaluation of Soy Germinated Embryo Extract

In order to prepare soybean germ extract, soybean germ was prepared according to the previous study of the present inventors. Specifically, soybean embryos were immersed in running water to germinate, and soybean germ embryos were harvested and lyophilized at about 24 hours, and powdered to obtain soybean germ powder. Fermented alcohol was added to the soybean germination powder thus obtained, followed by filtration to obtain a liquid component, and the liquid component was lyophilized to obtain a soybean germination extract.

Then, in order to confirm the safety of the soybean germ extract, the cytotoxicity of the extract against the cells was evaluated. Specifically, the progenitor cell lines 3T3-L1 were counted at 2 × 10 ² cells / well in 96 well plates, and the soybean germ extracts of 50, 100, 200, 300, 400 and 500 μg / mL concentrations were divided into the cells. Treated and incubated for 24 or 72 hours. After completion of the incubation, the water-insoluble formazan formed by the addition of the MTT solution was dissolved in a dimethyl sulfoxide solution, and the absorbance of the dissolved formazan was measured at 595 nm (optical density; OD value). Relative cell activity (%) was evaluated by measuring.

As a result, as shown in Figure 1, it was confirmed that the soybean germination extract does not exhibit cytotoxicity at all concentrations. Through this, it was found that the soybean germ extract of the present invention is a safe substance without harm to the human body.

Example 2 Analysis of the Effect of Soybean Germination Extracts on Adipocyte Differentiation

Example 2-1. Analysis of Fat Reduction Activity of Soy Germinated Embryo Extract

In order to confirm the anti-obesity effect of the extract, the effect of soybean germination extract on the degree of adipocyte differentiation was analyzed.

Specifically, 3T3-L1 cells (Korean Cell Line Bank, Korea) were purchased as 10% FBS (fetal bovine serum) and 1% antibiotic (antibiotics; 100 U / ml of penicillin and 0.1 mg / mL of steeptomycin). ) Was incubated at 37 ° C. under 5% CO ₂ (95% air) using DMEM (Dulbecco's modified eagle medium) medium.

Thereafter, the soybean germ extract prepared in the cultured 3T3-L1 cells was treated to the cells at concentrations of 50, 100, 200, 300, 400 and 500 μg / mL, and differentiated derivatives (FBS, IBMX, dexanmethasone and Insulin) was cultured in a medium containing 72 hours for differentiation into adipocytes. At this time, the control group was used as an adipocyte not treated with any substance, and the comparison group was used as an adipocyte treated with the same concentration of CLA (conjugated linoleic acid).

As a result, as shown in Figure 2, compared to the control cells (differentiated) control cells (differentiated), the insulin-differentiated control adipocytes (control + insulin) was confirmed to increase the fat accumulated in the cells. In addition, the soybean germination extract was confirmed to reduce the fat contained in the differentiated fat cells to a similar degree as the experimental group treated with CLA (conjugated linoleic acid), which is also used as a dietary supplement. It was confirmed that the fat reduction effect of the better the higher the concentration of the extract. In addition, the soybean germination extract of the present invention, when compared with the extract obtained by germinating the beans themselves, it was confirmed that the effect of inhibiting adipocyte differentiation is more excellent, and thus also the effect of inhibiting fat accumulation.

Example 2-2. Effect of Soybean Germination Extract on Adipocyte Differentiation

In order to analyze the effect of soybean germ extract on the differentiation of adipocytes, the effect of the extract on the expression of biomarkers related to adipocyte differentiation was investigated.

Specifically, the degree of protein expression of PPARγ, SREBP-1c and CEBPα, which are genes that promote the differentiation of adipocytes, was confirmed using Western blot method.

As a result, as shown in Figure 3, compared to the control cells treated with DMSO, in the experimental group treated with the extract it was confirmed that the expression of PPARγ, SREBP-1c and CEBPα decreases as the concentration of the extract increases. Through the above results, it can be seen that the soybean germination extract can inhibit the accumulation of fat cells by fat cells by inhibiting the differentiation of adipocytes. In addition, the soybean germ extract of the present invention, when compared with the extract (SG) obtained by germinating soybean itself, it was confirmed that the effect of inhibiting the expression of the gene is more excellent, thereby also inhibiting fat accumulation. .

Example 3. Analysis of the effect of soybean germ extract on adipose cells in vivo

Example 3-1. Effect of Soybean Germination Extract on Adipocyte Size

In order to evaluate the effect of the extract on the treatment of obesity, the effect of soybean germination extract on the fat cell size of the animal model inducing obesity by surgically removing the ovary was analyzed. After menopause, hormone metabolism decreases, basal metabolism decreases, and lipolysis decreases.

Specifically, the ovarian was removed using 8-week-old female C57BL / 6 mice to prepare a postmenopausal osteoporosis disease animal. After removal of the skin from the lower abdomen by 1-2cm, the ovary was used by forceps. ovary and oviducts were towed and excised. After one week of ovarian removal, randomized grouping was divided by weight measurement, and oral administration of soy germination embryo extract 0.1, 1 and 5 mg / kg 6 times a week using Sonde.

After the administration, 10% formalin fixation was performed by removing the adipose tissue around the uterine tissue, and the adipose tissue was sectioned to 4 μm through paraffin immobilization. Then, the microscope was performed with an optical microscope through HE (Hematoxylin and Eosin) staining. Specifically, the fat cells were observed at 400 times magnification, and the long and short axis lengths were measured for 10 cells in one field of view. The mean value of the major and minor axis observed at 3 o'clock per individual was calculated, and the average value of the group was calculated.

As a result, as shown in Figure 4, the obesity-induced obesity-induced negative control (OVX) compared to the normal control (con) it was confirmed that both shortening and long axis length of fat cells increased. On the other hand, the experimental group administered with the extract was confirmed that the diameter of the adipocytes decreased compared to the negative control, this effect was better as the concentration of the extract was higher, the higher concentration of the extract (5mg / kg / day) In the experimental group administered, it was confirmed that the size of the adipocytes decreased to a level similar to the normal control group.

Example 3-2. Effect of Soybean Germination Extract on White Adipocytes and Brown Adipocytes

White fat cells are the cause of adult diseases such as diabetes or obesity, whereas brown fat cells play a role of preventing fat by burning fat with energy, so to evaluate the therapeutic effect of the extract, soybean germination embryo extract The effect of this ovary removal on white fat cells or brown fat cells in the obese animal model was analyzed.

Specifically, the bean germination embryo extract was administered to the obesity-induced animal model by the method according to Example 3-1, and the number of white fat cells and brown fat cells of the animal was investigated. Fatty tissue cells undergo immunohistochemical staining using UCP1 (Mitochondrial uncoupling protein 1) protein involved in fatty acid oxidation, and then brown fat cells showing UCP1 positive response at 3 visual fields per microscope at 200-fold magnification. The number of was measured using LAS image analysis software.

As a result, as shown in FIG. 5, the negative control group (OVX) and the normal control group (con) induced by obesity due to menopause confirmed that the number of cells showing UCP1 positive response in and around gonadal fat was small. . On the other hand, the experimental group administered with the extract was confirmed to increase the number of cells showing a UCP1 positive response compared to the negative and normal control, it was confirmed that the size of the white adipocytes decreases at the same time. This effect was better as the concentration of the extract was higher, the experimental group administered the high concentration of the extract (5mg / kg / day), the number of brown fat cells compared to the control group did not receive about 3.2 times the increase was confirmed It was.

Through the above results, it can be seen that the soybean germ extract has an effect of inhibiting the accumulation of fat by reducing the size of the white fat cells and browning the cells.

From the above description, those skilled in the art will appreciate that the present invention can be implemented in other specific forms without changing the technical spirit or essential features. In this regard, the embodiments described above are to be understood in all respects as illustrative and not restrictive. The scope of the present invention should be construed that all changes or modifications derived from the meaning and scope of the following claims and equivalent concepts rather than the detailed description are included in the scope of the present invention.

Claims (11)

A pharmaceutical composition for preventing or treating obesity comprising soybean germ extract or fractions thereof. The composition of claim 1, wherein the soybean germination embryo is obtained by germinating an embryo isolated from soybean. The composition of claim 1, wherein the extract is obtained by extracting the bean germination embryos with water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof. The composition of claim 1, wherein the fraction is obtained by fractionating the extract with water, a lower alcohol having 1 to 4 carbon atoms, a nonpolar solvent, or a mixed solvent thereof. The composition of claim 1, wherein the extract inhibits the differentiation of adipocytes. The composition of claim 1, wherein the extract reduces the size of adipocytes. The composition of claim 1, wherein the extract converts white fat cells into brown fat cells. The composition of claim 1, wherein the composition further comprises a pharmaceutically acceptable carrier, excipient or diluent. A method for preventing or treating obesity, comprising administering the composition of any one of claims 1 to 8 to a subject other than a human. Food composition for the prevention or improvement of obesity comprising soybean germ extract or fractions thereof. Feed composition for the prevention or improvement of obesity comprising soybean germ extract or fractions thereof.

Images